Viking is developing what might be a game-changing medication in the segment.

The U.S. Food and Drug Administration has accepted Novo Nordisk's marketing application for an oral version of its ...

Health Canada begins a priority review of semaglutide 2.4 mg, a weekly treatment by Novo Nordisk for MASH, a liver disease ...

GLP-1 drug prices are falling. That's good news for patients, but perhaps not such good news for pharmaceutical stock ...

Canadian oil producer Imperial Oil posted a rise in first-quarter profit on Friday, driven primarily by stronger margins in ...

Britain's blue-chip index notched its 15th consecutive session of gains - its longest winning streak on record - as investors ...

The World Health Organization plans to officially back the use of weight-loss drugs to treat obesity in adults for the first ...

In an internal memo, the World Health Organization signaled its support for anti-obesity drugs like Wegovy and Zepbound, ...

With Wegovy in its portfolio, Novo Nordisk is a very good bet to continue being a winner. As it's currently considered something of an underdog, with its stock priced accordingly, it's also trading at ...

India's markets regulator has alleged Pranav Adani, director of several Adani group companies and the nephew of the ...

Eli Lilly on Thursday downplayed CVS Health's decision to drop the company's obesity drug Zepbound from some lists of ...

Amgen on Thursday said its first-quarter profit rose 24%, driven by product sales, and said that while it is premature to ...